TMX-049, Phase 2 Study

INTERVENTION: Intervention name : TMX‐049 Dosage And administration of the intervention : 5‐40mg,oral administration,once daily for 16 weeks Control intervention name : febuxostat INN of the control intervention : febuxostat Dosage And administration of the control intervention : 10‐40mg,oral administration,once daily for 16 weeks Control intervention name : placebo Dosage And administration of the control intervention : oral administration, once daily for 16 weeks CONDITION: hyperuricemia with or without gout PRIMARY OUTCOME: Percent change of serum urate from baseline to Week 16 SECONDARY OUTCOME: Percentage of subjects with serum urate =< 6.0 mg/dL at Week 16; Percent change of serum urate in each examination INCLUSION CRITERIA: Hyperuricemic patients with or without gout